
WW International: Equity Holders Face Near-Total Wipeout
When WW launched a new compounded semaglutide product late last year, the stock surged, renewing hopes of a growth revival. Back then, I warned investors that the struggles were far from over due to fundamental flaws in the company's business model. On …